Concert Pharma (CNCE) Tops Q4 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Concert Pharma (CNCE) Earnings 'Uneventful' Says Mizuho, Likes The CTP-692 Program
March 1, 2018 12:38 PM ESTMizuho Securities maintains Neutral on Concert Pharmaceuticals (NASDAQ: CNCE) price target of $23.00Concert Pharma (NASDAQ: CNCE).
Analyst Difel Yang called the Q4 earnings "uneventful" while stating a positive view on the announced CTP-692 candidate for the treatment of... More
Concert Pharma (CNCE) Sell-off Overdone - Stifel
March 1, 2018 12:26 PM ESTStifel maintains Buy on Concert Pharmaceuticals (NASDAQ: CNCE) price target of $27.00.
Analyst Adam Walsh says the sell-off following the shelf filing is overdone. With shares down over 15% Thursday the analyst believes the filing is a "non-event" as the company has over... More
Concert Pharma (CNCE) Announces Advancement of Novel Drug Candidate in Schizophrenia
February 28, 2018 4:24 PM ESTConcert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the next development candidate in its product pipeline with the selection of CTP-692, a novel drug for adjunctive treatment of schizophrenia, a devastating, chronic illness with... More
